Treatment Trials

8 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Registry for People With T-cell Lymphoma
      Description

      The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

      Conditions
      T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocytic LeukemiaChronic Lymphoproliferative Disorder of NK CellsAggressive NK-cell LeukemiaSystemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of ChildhoodChronic Active EBV Infection of T-and NK-Cell Type, Systemic FormHydroa Vacciniforme-Like Lymphoproliferative DisorderAdult T-cell Leukemia/LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeEnteropathy-associated T-cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaIntestinal T-Cell Lymphoma, Not Otherwise SpecifiedIndolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal TractHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaMycosis FungoidesSezary SyndromePrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Cutaneous T-cell LymphomaPrimary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell LymphomaPrimary Cutaneous Acral CD8-Positive T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeAnaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-negativeBreast Implant-Associated Anaplastic Large Cell Lymphoma
      Talk to us
      RECRUITING
      A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
      Description

      This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

      Conditions
      LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous T-Cell Lymphoma - CategoryPrimary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell LymphomaHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaAggressive NK Cell LeukemiaSystemic EBV1 T-cell Lymphoma, if CD8 PositiveHydroa Vacciniforme-Like Lymphoproliferative DisorderExtranodal NK/T Cell Lymphoma, Nasal TypeEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaIndolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI TractOther CD8+/NK Cell Driven Lymphoma Not Listed Above
      Talk to us
      COMPLETED
      MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
      Description

      This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAggressive NK-cell LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Eosinophilic LeukemiaChronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous LeukemiaIntraocular LymphomaJuvenile Myelomonocytic LeukemiaMast Cell LeukemiaMyeloid/NK-cell Acute LeukemiaNoncutaneous Extranodal LymphomaPost-transplant Lymphoproliferative DisorderPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaProgressive Hairy Cell Leukemia, Initial TreatmentProlymphocytic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificWaldenström Macroglobulinemia
      Talk to us
      COMPLETED
      Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
      Description

      This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

      Conditions
      Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Grade III Lymphomatoid GranulomatosisAdult Langerhans Cell HistiocytosisAdult Nasal Type Extranodal NK/T-cell LymphomaAggressive NK-cell LeukemiaAIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related MalignanciesAIDS-related Small Noncleaved Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Eosinophilic LeukemiaChronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous LeukemiaClear Cell Renal Cell CarcinomaCutaneous B-cell Non-Hodgkin Lymphomade Novo Myelodysplastic SyndromesEssential ThrombocythemiaExtramedullary PlasmacytomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaHIV InfectionHIV-associated Hodgkin LymphomaIntraocular LymphomaIsolated Plasmacytoma of BoneLight Chain Deposition DiseaseMast Cell LeukemiaMyelodysplastic Syndrome With Isolated Del(5q)Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyeloid/NK-cell Acute LeukemiaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaOsteolytic Lesions of Multiple MyelomaPeripheral T-cell LymphomaPlasma Cell NeoplasmPolycythemia VeraPost-transplant Lymphoproliferative DisorderPreviously Treated Myelodysplastic SyndromesPrimary MyelofibrosisPrimary Systemic AmyloidosisProgressive Hairy Cell Leukemia, Initial TreatmentProlymphocytic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Renal Cell CancerRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRefractory Multiple MyelomaRelapsing Chronic Myelogenous LeukemiaStage IV Renal Cell CancerT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaUnspecified Adult Solid Tumor, Protocol SpecificWaldenström Macroglobulinemia
      Talk to us
      TERMINATED
      Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
      Description

      RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.

      Conditions
      714leukemiaLymphoma
      Talk to us
      RECRUITING
      The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
      Description

      This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

      Conditions
      Lymphoid Malignancies
      Talk to us
      RECRUITING
      Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
      Description

      This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

      Conditions
      Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaEnteropathy-Associated T-Cell LymphomaHepatosplenic T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMediastinal (Thymic) Large B-Cell LymphomaNasal Type Extranodal NK/T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous Anaplastic Large Cell LymphomaRefractory Anaplastic Large Cell LymphomaSmall Lymphocytic LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
      Description

      This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

      Conditions
      Lymphoma, Non-HodgkinB-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaMantle Cell LymphomaIndolent LymphomaWaldenstrom MacroglobulinemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaAggressive LymphomaLarge-cell Lymphoma
      Talk to us